Where is Ventritex's headquarters?
Ventritex's headquarters is located at 10065 Red Run Blvd., Minneapolis.
What is Ventritex's latest funding round?
Ventritex's latest funding round is Acq - P2P.
Who are the investors of Ventritex?
Investors of Ventritex include St. Jude Medical, U.S. Venture Partners, InterWest Partners, MedVenture Associates, Sanderling Ventures and 4 more.
Who are Ventritex's competitors?
Competitors of Ventritex include Vertos Medical, Spineology, NinePoint Medical, Endotronix, Atria Medical and 13 more.
You May Also Like
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.
Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.